Pennytobuck Stock Report On Pwrm, Genz, Mnkd For August 16th, 2010.

Power3 Medical Products, Inc

Power3 Medical Products, Inc. (OTCBB:PWRM) announced that, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimers disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer NYSE:PFE), Exelon (Rivastigmine, Novartis NYSE:NVS), and Namenda (Memantine HCl, Forest Laboratories NYSE:FRX). These results relate to the genetically distinct groups of Alzheimers disease patients, i.e., those individuals who possess the Alzheimers high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

Genzyme Corporation (NASDAQ:GENZ) and Isis Pharmaceuticals Inc. (NASDAQ:ISIS) announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. In the study of patients with severe hypercholesterolemia, mipomersen reduced LDL-C, the primary endpoint, by 36 percent compared with a 13 percent increase for placebo. In the study of patients with high cholesterol at high cardiovascular risk, mipomersen reduced LDL-C by 37 percent compared with a 5 percent reduction for placebo. Both studies met all of their secondary endpoints. Frequently observed adverse events were injection site reactions, flu-like symptoms and elevations in liver transaminases, as seen in previous studies.

MannKind Corporation (Nasdaq:MNKD) announced the commencement of an offering of up to 8,000,000 shares of its common stock. The common stock being offered represent shares of MannKind common stock that MNKD will lend to Bank of America, N.A. Merrill Lynch, Pierce, Fenner & Smith Incorporated (Merrill Lynch), an affiliate of Bank of America, is acting as sole book-running manager for the offering. In connection with the common stock offering, MannKind will enter into a share lending agreement with Bank of America, pursuant to which MannKind will lend shares to Bank of America. Merrill Lynch intends to sell the borrowed shares in the common stock offering and to use the resulting short position to facilitate short sales and privately negotiated derivative transactions by which the investors in a concurrent private offering of $100 million aggregate principal amount of MannKinds Senior Convertible Notes due 2015 (or $115 million if the initial purchasers exercise their overallotment option in full), which is being made only to qualified institutional buyers, may hedge their investment in the notes. MannKind will not receive any proceeds from the offering but will receive a nominal one-time loan fee. Bank of America will be required to return the borrowed shares pursuant to the terms of the lending agreement.

For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

by: Bill Pennyman

POST COMMENT

Enjoying Bingo Today: Centuries Past And It Is Still Exhilarating Power Inverter Do's And Don'ts What Is A Short Sale And How Does The Process Work? Why go to Boot Camp and not just work out at a gym? Stock Update On Prot, Cur And Teva From Pennytobuck.com The Learners Most Excellent Fundamentals When Knowing Along With Participating Innumerable Enjoyable How Stock Study Evaluation Is Processed The Lg Optimus Looks Very Handsome And Very Sleek Bow Ties - The Good, The Bad And The Eccentric Getting Rid Of Feminine Odor Once And For All Ethical Relativism and the False Dichotomy The Pros and Cons of Argireline Which should we choose, monthly contacts and continuous contacts?